Skip to content
Clinical Trials – home

Kuopio University Hospital

Verified siteinfo

Finland Puijonlaaksontie 2, P. O. Box 1777, 70210 Kuopio, Finland

  • 38 trials recruiting
  • Breast cancer · Endometrial cancer · Plasma cell myeloma
  • Adults and children

About Specializations

Kuopio University Hospital in Kuopio, Finland specialises in clinical trials of conditions such as Breast cancer, Endometrial cancer, Plasma cell myeloma, Appendicitis, and other specialisations. This site conducts important research.

Main research areas of the site

Analytical, Diagnostic and Therapeutic Techniques and Equipment – Anesthesia and Analgesia

The pediatric department at Kuopio University Hospital is advancing pain control strategies for children undergoing surgery, testing newer analgesic protocols to reduce opioid exposure and improve recovery.

  • Post‑operative pain management in pediatric surgery
  • Regional anesthesia techniques for adolescents
  • Opioid‑sparing medication regimens

These studies aim to enhance comfort and safety for young patients while supporting faster discharge.

Analytical, Diagnostic and Therapeutic Techniques and Equipment – Diagnosis

Researchers are evaluating cutting‑edge diagnostic tools to enable earlier detection of serious conditions in children, including rapid imaging and biomarker panels.

  • Point‑of‑care ultrasound for abdominal emergencies
  • Multiplex blood tests for infection markers
  • Advanced imaging techniques for tumor staging

Accurate diagnosis supports timely treatment decisions across the hospital’s many therapeutic programs.

Diseases – Bacterial Infections and Mycoses

The site conducts trials on optimal antibiotic use and fungal infection management, seeking to balance efficacy with resistance prevention.

  • Acute otitis media treatment pathways
  • Antibiotic prophylaxis after gynecologic surgery
  • Diagnostic approaches for invasive fungal infections

Findings are expected to refine pediatric antimicrobial stewardship and improve outcomes.

Diseases – Cardiovascular Diseases

Cardiology investigators are testing antiplatelet regimens, blood‑pressure control strategies, and aneurysm‑monitoring protocols to reduce cardiovascular events in young and adult patients.

  • Dual antiplatelet therapy after coronary bypass
  • Home‑based blood pressure monitoring for hypertension
  • Early intervention for unruptured intracranial aneurysms

The goal is to lower rates of heart attacks, strokes, and aneurysm rupture.

Diseases – Digestive System Diseases

Trials focus on inflammatory gut disorders and postoperative recovery, including novel biologics for eosinophilic esophagitis and ulcerative colitis.

  • Tezepelumab for eosinophilic esophagitis
  • Biologic therapy in ulcerative colitis
  • Post‑appendectomy care pathways

These studies aim to improve quality of life and reduce disease‑related complications.

Diseases – Female Urogenital Diseases and Pregnancy Complications

Research includes antibiotic prophylaxis after hysterectomy and immunotherapy for endometrial cancer, seeking safer peri‑operative care and effective adjuvant treatments.

  • Azithromycin versus cefuroxime prophylaxis
  • Checkpoint inhibitor trials in advanced endometrial carcinoma
  • Hormonal therapy safety in reproductive‑age women

Outcomes will guide clinical guidelines for women’s health at Kuopio University Hospital.

Diseases – Hemic and Lymphatic Diseases

The oncology unit leads extensive work on blood‑cancer therapies, evaluating new antibodies and combination regimens for leukemias, lymphomas, and multiple myeloma.

  • Acute myeloid leukemia novel agents
  • Chronic lymphocytic leukemia targeted therapy
  • Diffuse large B‑cell lymphoma immunotherapy
  • Multiple myeloma combination studies

These investigations strive to improve survival and reduce treatment‑related toxicity.

Diseases – Immune System Diseases

Studies address autoimmune and inflammatory conditions, testing cytokine‑targeted drugs to alleviate symptoms and modify disease progression.

  • IL‑33 inhibition for chronic rhinosinusitis with nasal polyps
  • Anti‑IL‑5 therapy in eosinophilic disorders
  • Immune‑modulating agents for pediatric autoimmune disease

Success could expand therapeutic options for patients with refractory immune‑mediated illnesses.

Diseases – Male Urogenital Diseases

Prostate cancer research evaluates hormonal strategies and novel targeted agents to manage both castration‑sensitive and castration‑resistant disease.

  • Advanced metastatic prostate cancer trials
  • Hormone‑resistance reversal therapies
  • Advanced imaging for prostate tumor assessment

Findings aim to extend survival and maintain quality of life for men affected by prostate malignancies.

Diseases – Musculoskeletal Diseases

Investigations target hand contractures, frostbite injuries, and pediatric orthopedic trauma, focusing on functional recovery and scar reduction.

  • Dupuytren's contracture minimally invasive treatment
  • Iloprost versus tPA for severe frostbite
  • Rehabilitation protocols after pediatric fractures

The aim is to restore mobility and reduce long‑term disability.

Diseases – Neoplasms

A comprehensive oncology program tackles solid tumors and hematologic malignancies, testing immunotherapy, targeted agents, and maintenance strategies across cancer types.

  • HER2‑positive early breast cancer adjuvant therapy
  • Non‑small cell lung cancer combination trials
  • High‑risk cutaneous melanoma immunotherapy
  • Ewing sarcoma maintenance regimens
  • Ovarian cancer PARP inhibitor studies

Research strives to increase cure rates and offer personalized treatment options.

Diseases – Nervous System Diseases

Neurology investigators explore seizure control, infantile spasm prevention, and management of chronic subdural hematoma, integrating novel drugs and monitoring technologies.

  • XEN1101 for focal‑onset seizures
  • Vigabatrin prophylaxis for high‑risk infantile spasms
  • Anticoagulation strategies for chronic subdural hematoma
  • Advanced neuroimaging for seizure focus identification

Outcomes aim to reduce seizure frequency and improve neurological recovery.

Diseases – Respiratory Tract Diseases

Respiratory research includes chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and the impact of analgesic administration on breathing patterns.

  • COPD management with inhaled therapies
  • Anti‑fibrotic drug trials for idiopathic pulmonary fibrosis
  • Respiratory monitoring after oxycodone PCA

The goal is to preserve lung function and prevent respiratory complications.

Diseases – Skin and Connective Tissue Diseases

Dermatology studies assess adjuvant immunotherapy for high‑risk melanoma and evaluate treatments for cutaneous lymphomas and connective‑tissue disease biomarkers.

  • Short‑course immunotherapy after melanoma resection
  • Targeted therapy for cutaneous B‑cell lymphoma
  • Biomarker discovery in systemic sclerosis

These projects aim to improve skin cancer outcomes and advance care for rare connective‑tissue disorders.

Not possible to specify

Cross‑disciplinary initiatives integrate imaging innovation, multi‑omics profiling, and patient‑reported outcomes to support diverse therapeutic areas at Kuopio University Hospital.

  • Contrast‑enhanced ultrasound for superficial lymphatic mapping
  • Multi‑omics analyses in hematologic malignancies
  • Digital health tools for real‑time patient monitoring

These efforts enhance precision medicine and streamline trial conduct across the institution.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Puijonlaaksontie 2, P. O. Box 177770210 KuopioFinland
Recruiting now
38 trials
Conditions studied
75
Partner status
Verified site

More sites in KuopioFinland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

88 clinical trials

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.